Key result
Advances in understanding arrhythmia mechanisms, bioengineering, and clinical trials have driven the evolution of antiarrhythmic therapy over the past two decades.
Advances in understanding arrhythmia mechanisms, bioengineering, and clinical trials have significantly evolved the approach to antiarrhythmic therapy, moving towards targeted patient subsets and device therapies.
May guide individualized antiarrhythmic selection now; leaves open optimal integration of devices and targeted agents.
This review discusses the evolution in the approach to the therapy of cardiac arrhythmias that has occurred during the past 2 decades. The major changes have been driven by advances in understanding arrhythmia mechanisms, in bioengineering, and in clinical trials. It seems likely that progress in understanding the cellular and molecular basis of arrhythmias and their response to drug therapy may allow further identification of patient subsets in which specific therapies are indicated or contraindicated.
No takes yet. Share an insight, caveat, or question.
Dan M. Roden (1999) conducted a review in cardiac arrhythmias. Antiarrhythmic Therapy was evaluated. Advances in understanding arrhythmia mechanisms, bioengineering, and clinical trials have driven the evolution of antiarrhythmic therapy over the past two decades.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: